Takeshi Mochizuki1, Shigeki Momohara1, Katsunori Ikari1, Hiroshi Okamoto1, Shu Kobayashi1, So Tsukahara1, Takuji Iwamoto1, Koichiro Kawamura1, Seiji Saito1 and Taisuke Tomatsu1
11 August 2006
27 September 2006
Our aim was to determine whether the use of infliximab for rheumatoid arthritis (RA) patients is associated with an increased rate of postoperative complications. In this study we evaluated the serum concentration of infliximab to study the influence of autologous blood donation (AB donation) in patients who were administered infliximab and underwent total knee replacement (TKR). We examined five RA patients. Infliximab combined with methotrexate was administered at 3mg/kg every 8 weeks for all patients. We carried out the TKR operation in the middle of the 8-week interval in which infliximab was administered. The AB donation consisted of 400ml pooled AB drawn at one point 2 weeks following the final administration of infliximab. Serum infliximab levels were measured using an enzyme-linked immunosorbent assay. Mean serum infliximab levels were 5.46 ± 5.62?g/ml 2 weeks after the final administration of infliximab, 2.02 ± 1.66?g/ml just before the operation, and 1.48 ± 1.31?g/ml 1 day post operation. Moreover, the mean serum level in an autologous blood bag sampled just before AB donation was 5.02 ± 4.79?g/ml. This study indicated the serum level of infliximab in the stored blood remained at almost the same level as the collected autologous blood. However, even after autotransfusion those levels were decreased compared with levels measured just before the operation. Therefore, we conclude that there is little influence of AB donation on the risks of infliximab.
Autologous blood donation - Infliximab - Orthopaedic surgery - Rheumatoid arthritis - Total knee